Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
TFC 007 is an inhibitor of hematopoietic prostaglandin D synthase (H-PGDS; IC50 = 0.083 µM).1 It is selective for H-PGDS over lipocalin PGDS (L-PGDS) and microsomal PGE2 synthase (mPGES) at 100 µM. It is also selective for H-PGDS over COX-1, COX-2, 5-lipoxygenase (5-LO), leukotriene C4 (LTC4) synthase, and thromboxane (TX) synthase, as well as the histamine H1 and cysteinyl leukotriene 1 (CysLT1) receptors, at 10 µM. TFC 007 (30 mg/kg) inhibits antigen-induced increases in the production of PGD2 (Item No. 12010) in nasal cavity lavage fluid and reduces nasal blockage in a guinea pig model of allergic rhinitis.
WARNING This product is not for human or veterinary use.
1. Inhibition of hematopoietic prostaglandin D synthase improves allergic nasal blockage in guinea pigs. Prostaglandins Other Lipid Mediat. 95(1-4), 27-34 (2011).